TY - JOUR
T1 - IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease
AU - Ma, Hsiao Yen
AU - Yamamoto, Gen
AU - Xu, Jun
AU - Liu, Xiao
AU - Karin, Daniel
AU - Kim, Ju Youn
AU - Alexandrov, Ludmil B.
AU - Koyama, Yukinori
AU - Nishio, Takahiro
AU - Benner, Chris
AU - Heinz, Sven
AU - Rosenthal, Sara B.
AU - Liang, Shuang
AU - Sun, Mengxi
AU - Karin, Gabriel
AU - Zhao, Peng
AU - Brodt, Pnina
AU - Mckillop, Iain H.
AU - Quehenberger, Oswald
AU - Dennis, Ed
AU - Saltiel, Alan
AU - Tsukamoto, Hidekazu
AU - Gao, Bin
AU - Karin, Michael
AU - Brenner, David A.
AU - Kisseleva, Tatiana
N1 - Funding Information:
This study was supported by the National Institutes of Health ( R01 DK101737-01A1 , U01 AA022614-01A1 , R01 DK099205-01A1 , and P50AA011999 ) to TK and DAB; Herman Lopata Memorial Hepatitis Postdoctoral ALF Fellowship to JX; AI043477; P42 ES010337; U01 AA027681; R01 CA211794; and R01 DK120714 to MK.
Publisher Copyright:
© 2020 European Association for the Study of the Liver
PY - 2020/5
Y1 - 2020/5
N2 - Background & Aims: Chronic alcohol consumption is a leading risk factor for the development of hepatocellular carcinoma (HCC), which is associated with a marked increase in hepatic expression of pro-inflammatory IL-17A and its receptor IL-17RA. Methods: Genetic deletion and pharmacological blocking were used to characterize the role of IL-17A/IL-17RA signaling in the pathogenesis of HCC in mouse models and human specimens. Results: We demonstrate that the global deletion of the Il-17ra gene suppressed HCC in alcohol-fed diethylnitrosamine-challenged Il-17ra–/– and major urinary protein-urokinase-type plasminogen activator/Il-17ra–/– mice compared with wild-type mice. When the cell-specific role of IL-17RA signaling was examined, the development of HCC was decreased in both alcohol-fed Il-17raΔMΦ and Il-17raΔHep mice devoid of IL-17RA in myeloid cells and hepatocytes, but not in Il-17raΔHSC mice (deficient in IL-17RA in hepatic stellate cells). Deletion of Il-17ra in myeloid cells ameliorated tumorigenesis via suppression of pro-tumorigenic/inflammatory and pro-fibrogenic responses in alcohol-fed Il-17raΔMΦ mice. Remarkably, despite a normal inflammatory response, alcohol-fed Il-17raΔHep mice developed the fewest tumors (compared with Il-17raΔMΦ mice), with reduced steatosis and fibrosis. Steatotic IL-17RA-deficient hepatocytes downregulated the expression of Cxcl1 and other chemokines, exhibited a striking defect in tumor necrosis factor (TNF)/TNF receptor 1-dependent caspase-2-SREBP1/2-DHCR7-mediated cholesterol synthesis, and upregulated the production of antioxidant vitamin D3. The pharmacological blocking of IL-17A/Th-17 cells using anti-IL-12/IL-23 antibodies suppressed the progression of HCC (by 70%) in alcohol-fed mice, indicating that targeting IL-17 signaling might provide novel strategies for the treatment of alcohol-induced HCC. Conclusions: Overall, IL-17A is a tumor-promoting cytokine, which critically regulates alcohol-induced hepatic steatosis, inflammation, fibrosis, and HCC. Lay summary: IL-17A is a tumor-promoting cytokine, which critically regulates inflammatory responses in macrophages (Kupffer cells and bone-marrow-derived monocytes) and cholesterol synthesis in steatotic hepatocytes in an experimental model of alcohol-induced HCC. Therefore, IL-17A may be a potential therapeutic target for patients with alcohol-induced HCC.
AB - Background & Aims: Chronic alcohol consumption is a leading risk factor for the development of hepatocellular carcinoma (HCC), which is associated with a marked increase in hepatic expression of pro-inflammatory IL-17A and its receptor IL-17RA. Methods: Genetic deletion and pharmacological blocking were used to characterize the role of IL-17A/IL-17RA signaling in the pathogenesis of HCC in mouse models and human specimens. Results: We demonstrate that the global deletion of the Il-17ra gene suppressed HCC in alcohol-fed diethylnitrosamine-challenged Il-17ra–/– and major urinary protein-urokinase-type plasminogen activator/Il-17ra–/– mice compared with wild-type mice. When the cell-specific role of IL-17RA signaling was examined, the development of HCC was decreased in both alcohol-fed Il-17raΔMΦ and Il-17raΔHep mice devoid of IL-17RA in myeloid cells and hepatocytes, but not in Il-17raΔHSC mice (deficient in IL-17RA in hepatic stellate cells). Deletion of Il-17ra in myeloid cells ameliorated tumorigenesis via suppression of pro-tumorigenic/inflammatory and pro-fibrogenic responses in alcohol-fed Il-17raΔMΦ mice. Remarkably, despite a normal inflammatory response, alcohol-fed Il-17raΔHep mice developed the fewest tumors (compared with Il-17raΔMΦ mice), with reduced steatosis and fibrosis. Steatotic IL-17RA-deficient hepatocytes downregulated the expression of Cxcl1 and other chemokines, exhibited a striking defect in tumor necrosis factor (TNF)/TNF receptor 1-dependent caspase-2-SREBP1/2-DHCR7-mediated cholesterol synthesis, and upregulated the production of antioxidant vitamin D3. The pharmacological blocking of IL-17A/Th-17 cells using anti-IL-12/IL-23 antibodies suppressed the progression of HCC (by 70%) in alcohol-fed mice, indicating that targeting IL-17 signaling might provide novel strategies for the treatment of alcohol-induced HCC. Conclusions: Overall, IL-17A is a tumor-promoting cytokine, which critically regulates alcohol-induced hepatic steatosis, inflammation, fibrosis, and HCC. Lay summary: IL-17A is a tumor-promoting cytokine, which critically regulates inflammatory responses in macrophages (Kupffer cells and bone-marrow-derived monocytes) and cholesterol synthesis in steatotic hepatocytes in an experimental model of alcohol-induced HCC. Therefore, IL-17A may be a potential therapeutic target for patients with alcohol-induced HCC.
KW - ALD
KW - Alcoholic liver disease
KW - Cholesterol synthesis
KW - Fibrosis
KW - HCC
KW - Hepatocellular carcinoma
KW - IL-17 signaling
KW - Inflammation
KW - Mutational signatures
UR - http://www.scopus.com/inward/record.url?scp=85080024978&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85080024978&partnerID=8YFLogxK
U2 - 10.1016/j.jhep.2019.12.016
DO - 10.1016/j.jhep.2019.12.016
M3 - Article
C2 - 31899206
AN - SCOPUS:85080024978
SN - 0168-8278
VL - 72
SP - 946
EP - 959
JO - Journal of Hepatology
JF - Journal of Hepatology
IS - 5
ER -